Stanford Psychedelic Science Group
Welcome!
We are an interdisciplinary community of mental health professionals, trainees, students, and researchers dedicated to elevating the discussion about psychedelic science and medicine. Our mission is to offer free, high quality education, facilitate collaboration and mentorship, and promote the advancement of research into psychedelic substances and their effects in the domains of mental health, neuroscience, consciousness, and culture..
Education
Research
Contact
Upcoming Events
Fall Virtual Speaker Series
Wednesday, October 7 @ 12pm
Albert Garcia-Romeu, PhD
Albert Garcia-Romeu, PhD, is an Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine and a leading researcher on psychedelics, particularly psilocybin-assisted treatment for addiction. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research, and his work focuses on clinical applications of psychedelics, real-world drug use, spirituality and mental health, and diversity in science.
Wednesday, October 21 @ 12pm
Devon Christie, MD
Dr. Devon Christie is a physician, trauma therapist, and psychedelic researcher whose work explores the intersection of chronic pain, trauma, and psychedelic-assisted therapy. Her research includes the first published analysis demonstrating an association between MDMA-assisted therapy and reductions in chronic pain among people with PTSD, as well as a complex systems framework for understanding chronic pain and the potential roles of psychedelic therapies.
Wednesday, November 4 @ 5:30pm
Manesh Girn, PhD
Dr. Manesh Girn is a neuroscientist and psychedelic researcher whose work spans basic science, translational impact, and public education. Currently, he works as Co-Founder and Chief Executive Officer of Five Discovery, a biotechnology company developing psychedelic-inspired therapeutics for neurodegenerative disease. He also serves as Scientific Director of The Center for MINDS, a non-profit research organization exploring psychedelics and consciousness practices as catalysts for creativity and breakthrough insight in real-world, high-impact contexts.
Wednesday, November 18 @ 12pm
Chris Timmermann, PhD
Dr. Chris Timmermannis based at Imperial College London at the Centre for Psychedelic Research, where he led the first neuroimaging research on the effects of the potent psychedelic DMT on the human brain and consciousness, as well as its potential clinical applications. His work focuses on the neuroscience, psychology, beliefs, and ethics of the psychedelic experience. He is also a member of the international interdisciplinary group ALIUS and is the president of the Foundation for the Study of Human Consciousness (EcoH).
Past Events
Psychedelic Research at Stanford and Beyond
May 21st
6:00 - 6:25pm : Opening remarks, Psychedelics at Stanford, J. Christian Greer
6:25 - 7:15pm: Roundtable discussion, The Psychedelic Humanities, featuring J. Christian Greer, Tanya Luhrmann, Alex Gearin, & Nicholas Langlitz (moderated by Gianni Glick)
7:30 - 8:15pm: Roundtable discussion, Psychedelic Science at Stanford, with the Stanford Psychedelic Science Group featuring Gianni Glick, Boris Heifets, Trisha Suppes, Misha Carlson (moderated by Alex Gearin)
May 22nd
6:00 - 6:15: Opening remarks, The Future of Psychedelics at Stanford, J. Christian Greer
6:15 - 6:50: In conversation with AZA Allsop & Gianni Glick (moderated by Alex Gearin)
7:00 - 7:45pm: Roundtable discussion, Psychedelic Spiritual Care, featuring Jeffrey Breau & Jen Dillinger (moderated by J. Christian Greer )
7:45 - 8:30pm: Roundtable discussion, The Psychedelic Industry, featuring Nicholas Langlitz, Matthew Baggot, & Brian Anderson (moderated by Alex Gearin)
8:30-8:45pm: Closing remarks, J. Christian Greer
Speaker Series (2020-2026)
Eating Disorders & Psychedelic-Assisted Psychotherapy: Synergies & Urgently Needed Investigations
Marissa Raymond-Flesch, MD MPH
May 14, 2026
Turning Promise into Practice: The Pathway to Approving Psychedelic Treatments
Walter Dunn, MD PhD
April 30, 2026
Audiovisual Markers of Change in Psychedelic-Assisted Therapy
Lauren Lepow, MD
March 4, 2026
From Ancient Practices Comes the Birth of Consciousness-Based Psychopharmacology
Charles Raison, MD
January 21, 2026
Common Factors in Altered States: Understanding Psychedelic Therapy through Grawe’s General Change Mechanisms of Psychotherapy
Max Wolff, PhD
November 5, 2025
Psychedelic Drugs: Current Topics
Rick Strassman MD
October 8, 2025
Silencing the Pain Alarm: Psilocybin and Neural Signatures of Chronic Pain
Tess Veuthey, MD PhD
May 15, 2025
Psychedelics: Brain Mechanisms
Robin Carhart-Harris PhD
April 10, 2025
Therapeutic Potential of Psilocybin Therapy for Major Depressive Disorders
Sidney Zisook MD
March 5, 2025
Psychedelics, Beliefs, and Hallucinations
Philip Corlett PhD
May 1, 2023
Psychedelic-assisted therapy: lessons from clinical trial facilitation
Gisele Fernandes-Osterhold, MFT
April 13, 2023
Flyer
Questions, controversies, and opportunities for novel interventions for adults with OCD: psychedelics and ketamine
Carolyn Rodriguez, MD PhD
February 27, 2023
Flyer
When consciousness divides: the converging stories of ketamine and dissociation
David Mathai, MD
July 5, 2022
Flyer
On the fallibility of placebo control and how to address it: a case study in psychedelic microdosing
Balázs Szigeti, PhD
May 31, 2022
Flyer
Psychedelic Friction:
8 Controversies in Psychedelic Medicine
Alex Belser, PhD
October 14, 2021
Flyer
Ketamine-assisted Psychotherapy:
Organizing Ideas and Psychospiritual Themes
Kelley O'Donnell, MD PhD
August 31, 2021
Flyer
MAPS: MDMA-Assisted Therapy for PTSD and Beyond
Berra Yazar-Klosinski, Ph.D.
& Federico Menapace
June 25, 2021
Flyer
Therapeutic Effects of Psilocybin: Smoking Cessation and Beyond
Matthew Johnson, PhD
March 16, 2021
Flyer
The Long View of Psychedelic Research
George Greer MD, Heffter Research Institute
December 17, 2020
Flyer
Suggested reading: 1985 DEA Testimony and Greer and Tolbert 1998
The Rorschach Renaissance: Psychedelics as Cultural Projection
Imran Khan
May 28, 2026
Psilocybin treatment for alcohol use disorder: self-compassion and behavioral change
Kelley O'Donnell, MD PhD
February 18, 2026
Psychedelics, HPA Axis Activation, and Threat-Associated Behaviors
Cody Wenthur, PharmD PhD
February 4, 2026
Measuring and Enhancing Psychedelic Preparedness
Rosalind McAlpine, PhD
November 19, 2025
Psychedelics - A Trip Across Levels of Neuroscience
Josh Siegel MD PhD
October 22, 2025
Psilocybin for Mood Dysfunction in Parkinson's Disease
Ellen Bradley MD
April 24, 2025
Matt Baggott
Progress in Developing New Entactogens
April 3, 2025
Advancing Psilocybin Therapy: Challenges, Innovations, and Ethical Considerations
Josh Woolley MD PhD
January 22, 2025
The Potential Antidepressant Effects of Ayahuasca: Clinical and Preclinical Studies
Professor Nicole Galvão-Coelho
March 8, 2023
Flyer
Researching psilocybin therapy: current challenges and future prospects; bipolar disorder, SSRIs, and more
Josh Woolley, MD PhD
February 8, 2023
Flyer
A Cognitive-Behavioral Perspective on Avoidance and Acceptance in Psychedelic Therapy
Max Wolff, PhD
August 3, 2022
Flyer
The Acute and Enduring Effects of Hallucinogenic Drugs on Brain Function and Cognition
Manoj Doss, PhD
September 9, 2021
Flyer
Epigenetics in Psychedelic-Assisted Therapies: Spiritual Healing in Modern Healthcare
Joe Tafur, MD
July 19, 2021
Flyer
Psilocybin-facilitated Psychotherapy for Cocaine Dependence: Preliminary Findings
Peter Hendricks, PhD
February 23, 2021
Flyer
Psilocybin-assisted Therapy for Major Depression
Jordan Sloshower MD, MSc
November 10, 2020
Flyer
Suggested reading: Sloshower et al 2020